Skip to main content
main-content

Lymphoma

10-12-2018 | Lymphoma | News | Article

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

05-12-2018 | Lymphoma | News | Article

Editor's pick

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1804980
ASH 2018; San Diego, California, USA; 1–4 December

04-12-2018 | Lymphoma | Video

Two-year follow-up and high-risk subset analysis of ZUMA-1

Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:28).

04-12-2018 | Lymphoma | Video

Sustained disease control with tisagenlecleucel in refractory DLBCL setting

Richard Maziarz takes us through the long-term follow-up results of the JULIET trial indicating that the CAR T-cell therapy tisagenlecleucel has achieved a high response rate and enduring responses in adults with relapsed or refractory diffuse large B-cell lymphoma (6:38).

04-12-2018 | Lymphoma | Video

Reducing chemotherapy in younger diffuse large B-cell lymphoma patients

Viola Poeschel outlines findings from the FLYER trial, showing that a six-cycle R-CHOP plus rituximab regimen can be reduced to four cycles of R-CHOP plus rituximab without compromising efficacy in younger patients with diffuse large B-cell lymphoma and a favourable prognosis (4:33).

20-11-2018 | Oncology | News | Article

approvalsWatch

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

image credits